This subgroup analysis from an ongoing prospective study evaluates whether intraoperative in-vivo HSI enables rapid estimation of MGMT promoter methylation, potentially offering a practical, time-efficient tool for personalized decision-making in glioma surgery. The gene discussed is MGMT; the disease is glioma.